Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)

SHA:603590 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	307.86	189.98	230.2	345.25	599.08	1,347
Short-Term Investments	129.86	53.82	183.82	0.75	10.81	-
Trading Asset Securities	481.36	450.66	396.41	280.37	9.04	181.36
Cash & Short-Term Investments	919.08	694.46	810.43	626.36	618.93	1,528
Cash Growth	43.54%	-14.31%	29.39%	1.20%	-59.49%	-15.34%
Accounts Receivable	324.76	257.38	282.83	296.39	244.38	199.48
Other Receivables	32.37	33.84	35.56	27.73	6.31	38.26
Receivables	357.13	291.22	318.39	324.13	250.69	237.74
Inventory	59.3	72.38	48.47	36.99	47.02	33.94
Other Current Assets	16.19	28.48	52.67	29.23	31.19	8.54
Total Current Assets	1,352	1,087	1,230	1,017	947.83	1,808
Property, Plant & Equipment	413.86	426.73	414.54	440.14	407.06	329.61
Long-Term Investments	1,020	1,249	984.45	927.15	695.95	685.5
Goodwill	-	-	97.64	97.64	97.64	98.65
Other Intangible Assets	835.53	842.67	854.64	812.75	815.17	818.21
Long-Term Deferred Tax Assets	21.46	27.47	32.27	1.09	8.96	7.05
Long-Term Deferred Charges	288.63	234.36	150.71	120.45	82.41	0.02
Other Long-Term Assets	117.3	53.31	16.6	8.87	316.3	38.38
Total Assets	4,049	3,920	3,781	3,425	3,371	3,786
Accounts Payable	52.76	73.57	82.97	48.47	46.74	108.38
Accrued Expenses	35.01	45.68	32.15	26.82	33.99	35.02
Short-Term Debt	211.05	140.96	96.93	-	-	24.47
Current Portion of Long-Term Debt	-	1.07	5.12	-	-	-
Current Portion of Leases	9.19	7	3.95	8.71	7.5	-
Current Income Taxes Payable	19.31	4.69	0.25	34.12	15.84	8.69
Current Unearned Revenue	6.57	6.43	6.49	2.92	1.2	2.36
Other Current Liabilities	99.13	73.29	95.53	51.32	49.49	416.11
Total Current Liabilities	433.03	352.68	323.39	172.36	154.77	595.02
Long-Term Debt	55.31	49.85	43.78	-	-	-
Long-Term Leases	4.88	10.8	-	3.71	11.12	-
Long-Term Unearned Revenue	37.58	40.48	23.49	28.98	29.83	35.73
Long-Term Deferred Tax Liabilities	32.63	39.72	27.78	29.62	45.02	70.97
Total Liabilities	563.43	493.52	418.44	234.68	240.74	701.72
Common Stock	159.36	159.36	160	160	160	160
Additional Paid-In Capital	952.53	944.6	955.01	992.46	985.17	971.44
Retained Earnings	2,121	2,045	2,050	1,931	1,876	1,784
Treasury Stock	-19.19	-35.93	-78.59	-124.64	-124.64	-
Comprehensive Income & Other	-17.1	31.8	-26.5	-32.8	-8.11	163.35
Total Common Equity	3,197	3,144	3,060	2,926	2,889	3,078
Minority Interest	288.17	281.75	302.44	264.22	241.81	5.6
Shareholders' Equity	3,485	3,426	3,362	3,190	3,131	3,084
Total Liabilities & Equity	4,049	3,920	3,781	3,425	3,371	3,786
Total Debt	280.43	209.67	149.78	12.42	18.62	24.47
Net Cash (Debt)	638.65	484.79	660.65	613.94	600.31	1,504
Net Cash Growth	50.95%	-26.62%	7.61%	2.27%	-60.08%	-16.70%
Net Cash Per Share	4.07	3.10	4.22	3.93	3.81	9.43
Filing Date Shares Outstanding	159.68	159.22	158.98	156.49	156.49	157.67
Total Common Shares Outstanding	159.68	158.83	158.98	156.49	156.49	158.01
Working Capital	918.67	733.86	906.57	844.35	793.06	1,213
Book Value Per Share	20.02	19.80	19.25	18.70	18.46	19.48
Tangible Book Value	2,361	2,302	2,108	2,016	1,976	2,161
Tangible Book Value Per Share	14.79	14.49	13.26	12.88	12.63	13.68
Buildings	-	324.61	322.64	323.38	322.3	321.39
Machinery	-	126.83	125.74	126.76	114.72	109
Construction In Progress	-	209.85	190.8	181.98	127.26	47.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.